Ocumetics Technology Corp. (TSXV: OTC | OTCQB: OTCFF | FRA: 2QBO), the Calgary-based ophthalmology innovator, has announced two significant changes to its Board of Directors. The company has appointed entrepreneur and venture capitalist Sandi Gilbert as a new director, while President and CEO Dean Burns has been named Chairman of the Board. The moves signal a focus on capital markets expertise as Ocumetics continues to advance funding for its next growth stage.

Key Points

  • Ocumetics Technology Corp. (TSXV: OTC | OTCQB: OTCFF | FRA: 2QBO) announced two board-level changes on October 29, 2026
  • Sandi Gilbert appointed as Director; Dean Burns elevated to Chairman of the Board of Directors
  • Gilbert's appointment as director remains subject to TSX Venture Exchange approval
  • Investors may be watching how the strengthened board supports Ocumetics' ongoing funding efforts for its intraocular lens program

Sandi Gilbert Brings Capital Markets and Venture Expertise to Ocumetics Board

Sandi Gilbert is described in the announcement as an experienced entrepreneur and venture capitalist with a focus on helping organisations move from startup to scale-up. She is the founder of DealPoint, a fintech platform that digitises investor onboarding, investment execution, and compliance for private capital markets activities. Gilbert also leads InterGen, a not-for-profit initiative connecting emerging companies with senior Alberta business leaders, and serves as Managing Partner of InterGen Capital, a private venture fund. The release notes she sits on the board of the National Angel Capital Association and advises the Alberta Securities Commission's New Economy advisory board.

Dean Burns Assumes Chairman Role Alongside CEO Responsibilities

Concurrently with Gilbert's appointment, the company announced that Dean Burns, who serves as President and CEO of Ocumetics, has been appointed Chairman of the Board of Directors. The release states Burns commented that Gilbert's extensive capital markets experience "will be drawn on immediately" as the company works to secure funding for its next stage of growth. The announcement does not detail any changes to Burns' executive responsibilities or outline any separate appointment to fill a prior Chairman role, and the company did not disclose this figure in the announcement regarding any compensation arrangements.

Ocumetics' Dynamic Intraocular Lens Program Provides Growth Context

Ocumetics is currently in the first-in-human early feasibility study phase of its dynamic intraocular lens technology, which is designed to fit within the eye's natural lens compartment and potentially eliminate the need for corrective lenses. The device is intended to use the eye's natural muscle activity to shift focus between distances without glasses or contact lenses. The board changes arrive as the company continues to seek financing to advance this program, making the addition of capital markets-focused expertise on the board a development investors may be watching closely. The immediate share price impact was not clear from available public information.